| Advanced prostate cancer: treatment advances and future directions U Swami, TR McFarland, R Nussenzveig, N Agarwal Trends in cancer 6 (8), 702-715, 2020 | 168 | 2020 |
| Immune checkpoint inhibitors in prostate cancer S Venkatachalam, TR McFarland, N Agarwal, U Swami Cancers 13 (9), 2187, 2021 | 64 | 2021 |
| Treatment pattern and outcomes with systemic therapy in men with metastatic prostate cancer in the real-world patients in the United States U Swami, JA Sinnott, B Haaland, N Sayegh, TR McFarland, N Tripathi, ... Cancers 13 (19), 4951, 2021 | 33 | 2021 |
| Radium-223 plus enzalutamide versus enzalutamide in metastatic castration-refractory prostate cancer: final safety and efficacy results BL Maughan, A Kessel, TR McFarland, N Sayegh, R Nussenzveig, ... The Oncologist 26 (12), 1006-e2129, 2021 | 17 | 2021 |
| Evolving role of immunotherapy in metastatic castration refractory prostate cancer N Rathi, TR McFarland, R Nussenzveig, N Agarwal, U Swami Drugs 81, 191-206, 2021 | 13 | 2021 |
| Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine … E Lin, AW Hahn, RH Nussenzveig, S Wesolowski, N Sayegh, ... The Oncologist 26 (9), 751-760, 2021 | 9 | 2021 |
| Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results. A Kessel, TR McFarland, N Sayegh, K Morton, D Sirohi, M Kohli, U Swami, ... Journal of Clinical Oncology 39 (6_suppl), 135-135, 2021 | 5 | 2021 |
| Advanced prostate cancer: treatment advances and future directions. Trends Cancer. 2020; 6 (8): 702-15 U Swami, TR McFarland, R Nussenzveig, N Agarwal | 5 | |
| Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy … G Gebrael, N Sayegh, VM Thomas, B Chigarira, N Tripathi, YJ Jo, H Li, ... Prostate Cancer and Prostatic Diseases 27 (2), 279-282, 2024 | 4 | 2024 |
| Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations TR McFarland, A Kessel, U Swami, N Agarwal American Journal of Translational Research 13 (7), 7427, 2021 | 4 | 2021 |
| External validation of association of baseline circulating tumor cell counts with survival outcomes in men with metastatic castration-sensitive prostate cancer U Swami, N Sayegh, Y Jo, B Haaland, TR McFarland, RH Nussenzveig, ... Molecular cancer therapeutics 21 (12), 1857-1861, 2022 | 3 | 2022 |
| PARP inhibitors in prostate cancer: a promise delivered A Tripathi, T McFarland, N Agarwal European Urology Oncology 3 (5), 612-614, 2020 | 3 | 2020 |
| Overall survival (OS) with docetaxel (D) vs novel hormonal therapy (NHT) with abiraterone (A) or enzalutamide (E) after a prior NHT in patients (Pts) with metastatic prostate … U Swami, JA Sinnott, B Haaland, BL Maughan, N Rathi, TR McFarland, ... Journal of Clinical Oncology 38 (15_suppl), 5537-5537, 2020 | 3 | 2020 |
| Survival outcomes and characterization of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) undergoing intensified androgen deprivation therapy (ADT … N Sayegh, N Tripathi, B Chigarira, Y Jo, TR McFarland, A Kessel, ... Journal of Clinical Oncology 40 (6_suppl), 123-123, 2022 | 2 | 2022 |
| Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor … G Gebrael, N Sayegh, N Tripathi, D Goel, T McFarland, H Ebrahimi, ... Urology Practice 11 (1), 32-35, 2024 | 1 | 2024 |
| Detection of BRCA1, and BRCA2 Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting TR McFarland, V Mathew Thomas, R Nussenzveig, G Gebrael, N Sayegh, ... Biomedicines 10 (12), 3170, 2022 | 1 | 2022 |
| Transcriptomic profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (DN-mCSPC) versus those with mCSPC that have relapsed from prior … N Sayegh, B Chigarira, EJ Hernandez, TR McFarland, H Li, KK Sahu, ... Journal of Clinical Oncology 40 (16_suppl), 5080-5080, 2022 | 1 | 2022 |
| Progression-free survival (PFS) and overall survival (OS) in patients (pts) with de-novo, high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) undergoing … U Swami, B Chigarira, N Sayegh, TR McFarland, N Tripathi, ... Journal of Clinical Oncology 40 (6_suppl), 133-133, 2022 | 1 | 2022 |
| Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report TR McFarland, CE Tandar, N Agarwal, U Swami Cancer Treatment and Research Communications 29, 100480, 2021 | 1 | 2021 |
| Natural course of metastatic castration‐resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone‐sensitive setting G Gebrael, C Hage Chehade, N Sayegh, N Tripathi, B Chigarira, D Goel, ... The Prostate 84 (9), 888-892, 2024 | | 2024 |
